Sympathetic Regulation of Bone Metabolism

The sympathetic nervous system exerts a pivotal influence on skeletal homeostasis by modulating the activity of bone-forming osteoblasts and bone-resorbing osteoclasts. Noradrenaline released from sympathetic nerve terminals binds to β-adrenergic receptors on osteoblastic and osteoclastic lineage cells, leading to suppression of bone formation and enhancement of bone resorption. This neuro-endocrine loop integrates systemic cues such as circadian rhythms, stress signals and hormonal regulators including parathyroid hormone. Under conditions of heightened sympathetic tone—such as ageing, immobilisation or chronic stress—elevated β-adrenergic signalling accelerates bone loss, predisposing to osteoporosis. Conversely, selective blockade of this pathway with β-receptor antagonists or targeted modulation of downstream effectors can restore osteoblast function, inhibit osteoclastogenesis and improve fracture repair. Emerging evidence highlights microRNA-mediated control of osteoclast differentiation, genetic polymorphisms in adrenergic receptor genes that alter osteogenic capacity and the interplay between skeletal innervation and systemic serotonin levels. The global significance of these findings lies in new therapeutic avenues for metabolic bone disease, ranging from repurposed β-blockers to gene-based delivery systems and scaffold-mediated local drug release, all aimed at rebalancing bone remodelling under sympatho-adrenergic drive.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Sympathetic Regulation of Bone Metabolism publication trend

The graph below shows the total number of articles in sympathetic regulation of bone metabolism across all publications each year (not limited to Nature Index journals).

Technical terms

Sympathetic nervous system: Branch of the autonomic nervous system that releases noradrenaline to regulate involuntary functions, including bone remodelling.

Osteoblast: Bone-forming cell responsible for synthesis of collagen matrix and mineral deposition during bone formation.

Osteoclast: Bone-resorbing multinucleated cell that degrades mineralised matrix during bone turnover.

β-adrenergic receptor: G-protein-coupled receptor on bone and other cells that mediates the effects of catecholamines such as noradrenaline.

Osteoclastogenesis: Process by which mononuclear precursors differentiate into mature osteoclasts under signals such as RANKL and sympathetic cues.

References

1. β-Receptor blocker enhances the anabolic effect of PTH after osteoporotic fracture. Bone Research (2024).
2. Unraveling the Mechanism of Impaired Osteogenic Differentiation in Osteoporosis: Insights from ADRB2 Gene Polymorphism. Cells (2024).
3. Targeted inhibition of osteoclastogenesis reveals the pathogenesis and therapeutics of bone loss under sympathetic neurostress. International Journal of Oral Science (2022).
4. Blockade of adrenergic β‐receptor activation through local delivery of propranolol from a 3D collagen/polyvinyl alcohol/hydroxyapatite scaffold promotes bone repair in vivo. Cell Proliferation (2019).
5. Unloading Induces Osteoblastic Cell Suppression and Osteoclastic Cell Activation to Lead to Bone Loss via Sympathetic Nervous System*. Journal of Biological Chemistry (2005).